Onconova Therapeutics Inc. to Present Data Demonstrating Survival Benefit in MDS Patients Treated with Rigosertib and Phase I Data for Oral Rigosertib at the American Society of Hematology Annual Meeting  
12/12/2011 10:26:32 AM

NEWTOWN, Pa. & PENNINGTON, N.J.--(BUSINESS WIRE)--Onconova Therapeutics announces three presentations relating to clinical trials of its Phase III-stage anticancer agent, rigosertib sodium (Estybon® or ON 01910.Na), at the 53rd American Society of Hematology (ASH) Annual Meeting in San Diego, CA, December 10-13, 2011. The presentations highlight data from five clinical trials with rigosertib for myelodysplastic syndrome (MDS) in both intravenous and oral formulations as well as identification of biomarkers employing a nano-immunoassay (NIA) in bone marrow cells from MDS patients in clinical trials.